New method to evaluate cancer prognosis

The present invention relates to the prediction and treatment of cancers. In this study, the inventors analyzed how invalidation of the mitochondrial nucleoside diphosphate kinase (NDPK-D) functions affects the cellular behavior. HeLa cells, which naturally express low levels of NDPK-D, were stably transfected with expression vectors, either empty or designed to express NDPK-D wild type or mutant proteins. Single point mutations were chosen to suppress either the catalytic NDPK activity or its ability to bind the mitochondria inner membrane. Both loss-of-function mutations promoted altered mitochondrial structure and function, epithelial-mesenchymal transition and increased migratory and invasive potential. Immunocompromised mice developed more metastases when injected with cells expressing mutant NDPK-D as compared to wild-type. In human cancer, NME4 expression is negatively associated with tumor aggressiveness, and is a good prognosis factor for beneficial clinical outcome. Thus, the invention relates to a method for predicting the survival time of a patient suffering from a cancer comprising determining the expression level of NDPK-D and to the treatment of cancer in a subject in need thereof by using the NDPK-D protein or a fragment thereof or a fusion protein thereof and/or an agent for NDPK-D protein expression.

Patent Application number: PCT/EP2022/050446 on 11/01/2022
BMC Biol 2021 Oct 21 Lacombe Marie-Lise et al. The mitochondrially-localized nucleoside diphosphate kinase D (NME4) is a novel metastasis suppressor doi: 10.1186/s12915-021-01155-5.



Business Developper
Pierre MAZOT
Pierre MAZOT
Business Developer
Patent filling date: 2022-01-11

You might also be interested in